Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B

NCT02283671 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis
Neuromyelitis Optica

Interventions

BIOLOGICAL: Tolerogenic Dendritic cells loaded with myelin peptides

Sponsor

Sara Varea